EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring

Valentina D'Atri iD, Fabrizio Corrado, François Versace iD, Susana Alves Saldanha, Thomas Mercier iD, Monia Guidi iD, Paul Thoueille iD, Sylvain Blanchon iD, Angela Koutsokera iD, Michael Vogeser, Catia Marzolini iD, François Girardin iD und 6 weitere

Molecules · 2025

DOI: 10.3390/molecules30091866 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Valentina D'Atri und 17 weiteren Autor:innen. Beteiligte Einrichtung: Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Laus…. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Cystic Fibrosis, Drug Monitoring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cystic Fibrosis Switzerland and the Swiss Working Group for Cystic Fibrosis (SWGCF), SNF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is a life-threatening disorder caused by mutations in the CFTR gene, leading to defective chloride ion transport and thickened mucus in the respiratory and gastrointestinal systems. CFTR modulators, including ivacaftor, lumacaftor, tezacaftor, and elexacaftor, have improved patient outcomes, but interindividual pharmacokinetic variability and potential drug–drug interactions require therapeutic drug monitoring (TDM) for optimal efficacy and safety. In this context, a liquid chromatography–tandem mass spectrometry (LC-MS/MS) method has been developed and validated for the simultaneous quantification of CFTR modulators and their major active metabolites in human plasma to support pharmacokinetic studies and routine TDM. The multiplex LC-MS/MS assay was established using plasma protein precipitation, followed by chromatographic separation on an Xselect HSS T3 (Waters®) column and positive electrospray ionization mode detection. The method was validated based on FDA and EMA guidelines for specificity, linearity, accuracy (89.8–107.8%), repeatability (1.1–8.1%), intermediate fidelity (1.3–10.9%), matrix effects, and stability, demonstrating a robust performance with excellent precision and accuracy. International interlaboratory comparisons confirmed the reliability of the assay. The developed method can be applied for the clinical monitoring of caftors’ plasma concentrations and preliminary data suggest that it can also be applied to alternative matrices, such as breast milk. This method will serve to characterize caftors’ pharmacokinetic variability and monitor drug–drug interactions to further refine personalized dosing strategies and enhance precision medicine treatments for patients with CF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tandem Mass SpectrometryCystic FibrosisDrug MonitoringHumansChromatography, LiquidCystic Fibrosis Transmembrane Conductance RegulatorQuinolonesAminophenolsAminopyridinesBenzodioxolesReproducibility of ResultsIndoles

Stichwörter der Autor:innen

CFTR modulatorsLC-MS/MScystic fibrosismethod developmentpharmacokineticsprecision medicinequantificationtherapeutic drug monitoringvalidation

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorQuinolonesAminophenolsivacaftorAminopyridinesBenzodioxoleslumacaftortezacaftorCFTR protein, humanIndoles

Autor:innen und Institutionen

  • Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Center for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Pediatric Pneumology and Cystic Fibrosis Unit, Division of Pediatrics, Department Woman-Mother-Child, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Adult Cystic Fibrosis and CFTR-Related Disorders Center, Division of Pulmonology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
  • Institute of Laboratory Medicine, LMU University Hospital, 81377 Munich, Germany.
  • Division of Pulmonology, Department of Medicine, Neuchâtel Hospital Network, 2000 Neuchâtel, Switzerland.

ORCID-Profile: Valentina D'Atri, François Versace, Thomas Mercier, Monia Guidi, Paul Thoueille, Sylvain Blanchon, Angela Koutsokera, Catia Marzolini, François Girardin, Georgia Mitropoulou, Isabelle Rochat, Laurent Arthur Decosterd, Eva Choong

Förderung

  • Cystic Fibrosis Switzerland and the Swiss Working Group for Cystic Fibrosis (SWGCF)
  • SNF

Zitieren

APA

D'Atri, V., Corrado, F., Versace, F., Saldanha, S. A., Mercier, T., Guidi, M., Thoueille, P., Blanchon, S., Koutsokera, A., Vogeser, M., Marzolini, C., Girardin, F., Mitropoulou, G., Balmpouzis, Z., Rochat, I., Sauty, A., Decosterd, L. A., & Choong, E. (2025). A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules. https://doi.org/10.3390/molecules30091866

Vancouver

D'Atri V, Corrado F, Versace F, Saldanha SA, Mercier T, Guidi M, et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring. Molecules. 2025. doi:10.3390/molecules30091866

BibTeX
@article{DAtri2025,
  author = {D'Atri, Valentina and Corrado, Fabrizio and Versace, François and Saldanha, Susana Alves and Mercier, Thomas and Guidi, Monia and Thoueille, Paul and Blanchon, Sylvain and Koutsokera, Angela and Vogeser, Michael and Marzolini, Catia and Girardin, François and Mitropoulou, Georgia and Balmpouzis, Zisis and Rochat, Isabelle and Sauty, Alain and Decosterd, Laurent Arthur and Choong, Eva},
  title = {A Liquid Chromatography-Tandem Mass Spectrometry Method for the Quantification of Cystic Fibrosis Drugs (Caftors) in Plasma and Its Application for Therapeutic Monitoring},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30091866}
}
Kostenlos starten →